Skip to content

Amphastar Pharmaceuticals, Inc.

AMPH· Nasdaqxbrl foundCIK 1297184

Pharmaceutical preparations552 peers

Last sale
Oct 30, 2026 · +2.89%
Market cap
$1.18B
42.65M shares
Filings
959
$207.61M
Q3 2026−1.7% FY25 yoy
$37.76M
Q3 2026−38.5% FY25 yoy
$50.77M
Q3 2026−31.7% FY25 yoy
$114.42M
Q3 2026derived−29.7% FY25 yoy
$0.87
Q3 2026−33.7% FY25 yoy
$204.59M
Q3 2026+12.2% FY25 yoy
$1.18B
12.0×
1.6×
1.5×
11.75%
—

Twelve months to Sep 30, 2026 · derived

Price

$27.73+14.44%+$3.50past year
Oct 30, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$719.89MFY 2025
$731.97M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$719,887,000reported
FY 20242024-12-31$731,967,000reported
FY 20232023-12-31$644,395,000reported
FY 20222022-12-31$498,987,000reported
FY 20212021-12-31$437,768,000reported
FY 20202020-12-31$349,846,000reported
FY 20192019-12-31$322,357,000reported
FY 20182018-12-31$294,666,000reported
FY 20172017-12-31$240,175,000reported
FY 20162016-12-31$255,165,000reported
FY 20152015-12-31$251,519,000 revisedreported
FY 20142014-12-31$210,461,000reported

Capital returns

Dividends and buybacks · FY2016 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$75.59M$75.59M—45.37M sh−4.8%62.3%
FY2024—$85.46M$85.46M—47.65M sh−0.9%49.6%
FY2023—$58.14M$58.14M—48.10M sh+0.4%40.0%
FY2022—$39.91M$39.91M—47.90M sh−0.5%61.3%
FY2021—$28.87M$28.87M—48.15M sh+1.5%40.9%

Segments

Revenue by Segments, FY2018 to FY2025FY2018Active Pharmaceutical Ingredient Segment · FY2018 · $23.61MFinished Pharmaceutical Products Segment · FY2018 · $271.06MFY2019Active Pharmaceutical Ingredient Segment · FY2019 · $20.36MFinished Pharmaceutical Products Segment · FY2019 · $302.00MFY2020Active Pharmaceutical Ingredient Segment · FY2020 · $18.48MFinished Pharmaceutical Products Segment · FY2020 · $331.37MFY2021Active Pharmaceutical Ingredient Segment · FY2021 · $18.20MFinished Pharmaceutical Products Segment · FY2021 · $419.57MFY2022Pharmaceutical products segment · FY2022 · $498.99MActive Pharmaceutical Ingredient Segment · FY2022 · $12.48MFinished Pharmaceutical Products Segment · FY2022 · $486.51MFY2023Pharmaceutical products segment · FY2023 · $644.40MActive Pharmaceutical Ingredient Segment · FY2023 · $14.12MFinished Pharmaceutical Products Segment · FY2023 · $630.27MFY2024Pharmaceutical products segment · FY2024 · $731.97MFY2025Pharmaceutical products segment · FY2025 · $719.89M
LineFY2025ShareChange
Pharmaceutical products segment$719.89M100%−1.7%
Active Pharmaceutical Ingredient Segment———
Finished Pharmaceutical Products Segment———
Total$719.89M

From the 10-K filed Feb 26, 2026AMPH

Pharmaceutical preparations

Amphastar Pharmaceuticals, Inc. is the 45th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR